China

State-owned China Petrochemical Corp (Sinopec) raised $2bn from three dollar bonds on Monday, making a rapid comeback to the debt market.

Six Chinese real estate issuers — mostly high yield — flooded the dollar bond market on Monday with one to four year tenor deals. Investment grade rated China Vanke Co, on the other hand, tapped the longer end of the curve with a dual-tranche issuance.

China Construction Bank’s Singapore branch joined the offshore renminbi bond issuance party on Monday with a Rmb1bn ($142m) two year deal.

Pharmaron Beijing Co, a Chinese pharmaceutical research and development service platform, started testing investor appetite for its IPO on Monday.

BMW Auto Finance (China) is planning a return to the auto loan ABS market next week with a Rmb8bn ($1.1bn) deal.

Shanghai Fosun Pharmaceutical Group, which bought Indian company Gland Pharma in 2016, is planning to list the subsidiary on the National Stock Exchange of India and the BSE.

In this round-up, the US and China held another round of phone calls on trade last Friday, China officially launched the 5G mobile network and the rise in Caixin Purchasing Managers’ Index (PMI) was at odds with the slump in the official PMI.

Hutchison Port Holdings Trust seized the market window immediately after the Federal Open Market Committee meeting to sell a $500m five year bond on Thursday.

Chinese biopharmaceutical firm 3SBio has taken one step closer to spinning off and listing a unit on Shanghai’s Nasdaq-style Star Market.

Central China Real Estate priced a $200m four non-call two year bond on Thursday, after surprisingly strong demand allowed it to tighten pricing aggressively.

Goldman Sachs’ co-head of China investment banking Hansong Zhu is retiring after 19 years with the bank, according to an internal memo seen by GlobalCapital Asia.

Chinese pharmaceuticals firm WuXi Biologics and one of its controlling shareholders are set to raise a combined HK$7.9bn ($1bn) from the sale of equal chunks of shares in the company.